India is currently witnessing nearly two million heart attacks a year and majority of the victims are youngsters.
Almost 2 million individuals in the India have heart problems. Throughout the last several years, there have been some truly significant advances in heart problems treatment which are now moving rapidly toward widespread availability. Following a decade of failed efforts at developing new heart drugs, a major treatment breakthroughs are nearing FDA approval in last decade. They might help patients who’ve benefited adequately from existing therapies. Congestive heart failure is a very common disorder characterized by a failure of the heart muscle to forcefully pump blood to the body’s tissues. Heart attacks, high blood pressure level, or diseases that weaken the heart muscle are common causes.
Patients frequently have severe difficulty breathing or fatigue that limits their capability to enjoy life. This disorder is the most typical reason behind hospital admission among Medicare patients. In a large clinical trial, known as EECP® Therapy, the treatment was used to treat heart failure, and it was extremely effective. Currently, 20 percent or more of patients hospitalized for heart failure are re admitted within 1 month. This represents a significant burden for patients and the healthcare system. EECP® Therapy
the new treatment called Enhanced External Counter Pulsation (EECP). This is the only non-invasive, non- pharmaceutical treatment approved by USFDA.